psi-6130 psi-6130 psi-6130 is an experimental treatment for hepatitis c. psi-6130 is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist jeremy l. clark. specifically, psi-6130 inhibits the hepatitis c virus rna dependant rna polymerase called ns5b. psi-6130clinical dataatc codenoneidentifiers iupac name 4-amino-1-((2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1h)-one cas number817204-33-4 ypubchem cid6481236chemspider4981776unii05j68784g1chemblchembl223482comptox dashboard (epa)dtxsid10231287 chemical and physical dataformulac10h14fn3o4molar mass259.237 g·mol−13d model (jsmol)interactive image smiles c1(((o1n2ccc(nc2=o)n)co)o)f inchi inchi=1s/c10h14fn3o4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16h,4h2,1h3,(h2,12,13,17)/t5-,7-,8-,10-/m1/s1key:nypirlymdjmkgw-vpcxqmtmsa-n (verify) psi-6130 is currently being developed by hoffmann–la roche as a 3',5'-diisobutyrl ester prodrug, r7128. r7128 is part of the combination of all-oral agents clinical trial known as inform-1.